VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ALC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ALCAlcon Inc.
$66.87$32.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ALC logoAlcon Inc.(ALC)Earnings, Financials & Key Ratios

ALC•NYSE
$66.87
33.8× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryDental and vision care devices
AboutAlcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.Show more
  • Revenue$10.4B+4.9%
  • EBITDA$2.55B-3.4%
  • Net Income$980M-3.7%
  • EPS (Diluted)1.98-3.4%
  • Gross Margin55.24%-0.7%
  • EBITDA Margin24.53%-8.0%
  • Operating Margin13.08%-8.3%
  • Net Margin9.42%-8.3%
  • ROE4.5%-6.8%

ALC Price & Volume

Alcon Inc. (ALC) stock price & volume — 10-year historical chart

Loading chart...

Steady Revenue Growth Amidst Operating Margin Volatility

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Stable
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Operating margin volatility

Key Thesis Takeaways

  • Alcon demonstrates a consistent top-line expansion with 7.3% year-over-year revenue growth as of 2026Q1, supported by a robust $31.8 billion asset base.
  • However, investors should monitor the significant volatility in operating margins, which fluctuated from 18.9% in 2025Q1 to 11.5% in 2025Q4, alongside high SG&A expenses that consistently consume over 30% of revenue.
  • While the conservative 0.24x debt-to-equity ratio provides financial flexibility, the reliance on $9.3 billion in goodwill and erratic free cash flow margins warrants a cautious approach to long-term valuation.

Verdict Logic

while the firm maintains steady 7.3% revenue growth, the significant volatility in EPS, which dropped from $0.70 in 2025Q1 to $0.38 in 2026Q1, suggests that operational efficiency remains a critical risk factor.

ALC Growth Metrics

Alcon Inc. (ALC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years4.78%
5 Years8.77%
3 Years6.06%
TTM6.61%

Profit CAGR

10 Years12.71%
5 Years-
3 Years43.02%
TTM-27.2%

EPS CAGR

10 Years12.5%
5 Years-
3 Years42.8%
TTM-26.67%

Return on Capital

10 Years1.48%
5 Years3.73%
3 Years4.6%
Last Year4.81%

ALC Recent Earnings

Alcon Inc. (ALC) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 5, 2026
Metric
Actual
Est
EPS
$0.85+6.3%
$0.80
Rev
$2.7B+0.4%
$2.6B
Q1 2026
Feb 24, 2026
Metric
Actual
Est
EPS
$0.78-1.3%
$0.79
Rev
$2.6B-1.9%
$2.7B
Q4 2025
Nov 11, 2025
Metric
Actual
Est
EPS
$0.79+2.6%
$0.77
Rev
$2.6B-3.6%
$2.7B
Q3 2025
Aug 19, 2025
Metric
Actual
Est
EPS
$0.76+7.0%
$0.71
Rev
$2.6B-2.1%
$2.7B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 5, 2026
$0.85vs $0.80+6.3%
$2.7Bvs $2.6B+0.4%
Q1 2026Feb 24, 2026
$0.78vs $0.79-1.3%
$2.6Bvs $2.7B-1.9%
Q4 2025Nov 11, 2025
$0.79vs $0.77+2.6%
$2.6Bvs $2.7B-3.6%
Q3 2025Aug 19, 2025
$0.76vs $0.71+7.0%
$2.6Bvs $2.7B-2.1%
Based on last 12 quarters of dataView full earnings history →

Latest ALC News

Recent stock market news and headlines for Alcon Inc. (ALC)

GlobeNewsWire·1 day ago
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).

Globe News Wire·1 day ago
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies Collaboration aims to combine best-in-class PCIOL optics with first-in-class platform to enable fine-tuning of visual outcomes after cataract surgery ALISO VIEJO, Calif. , July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc.

Zacks Investment Research·1 day ago
Here's Why Alcon (ALC) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research·5 days ago
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

Alcon's new platforms, lenses and dry eye momentum support growth, but macro pressures, tariffs and fierce competition weigh on its outlook.

PRNewsWire·Jun 29, 2026
MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors

David Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experience; Linnea Burman adds MedTech operating depth NORTHRIDGE, Calif., June 29, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that David Endicott and Linnea Burman have joined its Board of Directors, effective today, expanding the Board from nine to 11 members.

Peers Comparison

Key metrics vs top competitors for Alcon Inc. (ALC)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ALC logoALCAlcon Inc.Current
$66.87$32.59B33.774.94%9.42%4.5%0.5%
BAX logoBAXBaxter International Inc.
$22.86$11.8B-13.065.72%-9.7%-16.5%—
HSIC logoHSICHenry Schein, Inc.
$86.84$9.89B26.564.03%2.95%8.14%—
HOLX logoHOLXHologic, Inc.
$76.01$16.97B30.531.74%13.18%11.01%—
IDXX logoIDXXIDEXX Laboratories, Inc.
$570.25$45.29B43.6010.42%24.63%70.87%—
EW logoEWEdwards Lifesciences Corporation
$94.82$54.6B51.8111.55%17.34%10.54%—

Compare ALC vs Peers

Alcon Inc. (ALC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BAX

Most directly comparable listed peer for ALC.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ALC against a more recognizable public peer.

Peer Set

Compare Top 5

vs BAX, HSIC, HOLX, IDXX

Get notified when ALC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ALC Frequently Asked Questions

Alcon Inc. (ALC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Alcon Inc.'s revenue?

Alcon Inc. (ALC) reported $10.58B in revenue for fiscal year 2025. This represents a 62% increase from $6.52B in 2015.

How fast is Alcon Inc. growing?

Alcon Inc. (ALC) grew revenue by 4.9% over the past year. Growth has been modest.

Is ALC profitable?

Yes, Alcon Inc. (ALC) is profitable, generating $815.3M in net income for fiscal year 2025 (9.4% net margin).

Dividend & Returns
Does ALC pay dividends?

Yes, Alcon Inc. (ALC) pays a dividend with a yield of 0.50%. This makes it attractive for income-focused investors.

What is ALC's return on equity?

Alcon Inc. (ALC) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.

What is Alcon Inc.'s free cash flow?

Alcon Inc. (ALC) generated $1.70B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in ALC back in 2015?

Total return calculator · dividends reinvested · 11+ years of data

See returns →